NICE has extended the range of indications that Novartis' Cosentyx can be prescribed for by the NHS in England, giving a green light for its use in non-radiographic axial spondyloarthritis
Sanofi has licensed a potential inflammatory diseases drug from Manchester University spin-off C4X Discovery Holdings in a deal worth up to €414 million ($492 million).
Amgen has announced its second acquisition in the space of a month, snapping up Rodeo Therapeutics and its potential tissue repair drugs in a deal worth up to $721 million.
A phase 3 trial of Lilly’s inflammatory diseases challenger mirikizumab in ulcerative colitis has met its target – potentially adding further competition to a crowded market.
Eleven new digital health start-ups have graduated from PharmStars’ twice-yearly education and mentoring programme, with the latest crop focusing on digital innovations in
On 1st October, the roll-out of the National Contract Value Review (NCVR) process marked a pivotal moment in the trajectory of clinical research in the UK, introducing a standardised, natio